LSTA — Lisata Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $45.25m
- $29.04m
- $0.17m
Annual cashflow statement for Lisata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 52 W | 52 W | 52 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.5 | -54.2 | -20.8 | -20 | -16.6 |
| Depreciation | |||||
| Non-Cash Items | 4.52 | 33.8 | 1.08 | 1.33 | 1.78 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.647 | -0.831 | -0.462 | -0.873 | -1.29 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -22.2 | -21.2 | -20 | -19.4 | -15.9 |
| Capital Expenditures | -0.06 | -0.285 | 0 | — | -0.028 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -54.8 | 29.2 | 10.1 | 13.2 | 15.1 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -54.9 | 28.9 | 10.1 | 13.2 | 15.1 |
| Financing Cash Flow Items | -0.248 | -0.267 | -0.091 | -0.274 | -0.253 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 85.3 | -0.224 | 0.385 | -0.206 | 0.599 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.13 | 7.51 | -9.56 | -6.38 | -0.253 |